| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 10.358 | 15.198 | 18.375 | 17.448 | 18.386 | 22.013 | 17.251 | 13.865 | 13.512 | - |
| Total Income - EUR | 10.358 | 15.198 | 18.375 | 17.448 | 18.386 | 22.013 | 17.251 | 13.865 | 13.512 | - |
| Total Expenses - EUR | 16.850 | 21.584 | 28.223 | 25.478 | 25.507 | 28.367 | 24.090 | 18.887 | 17.072 | - |
| Gross Profit/Loss - EUR | -6.492 | -6.385 | -9.848 | -8.029 | -7.121 | -6.354 | -6.839 | -5.022 | -3.560 | - |
| Net Profit/Loss - EUR | -6.802 | -6.538 | -10.032 | -8.204 | -7.305 | -6.556 | -7.011 | -5.161 | -3.695 | - |
| Employees | 3 | 3 | 3 | 2 | 2 | 2 | 0 | 2 | 2 | - |
Check the financial reports for the company - Andocrin S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Current Assets | 3.455 | 4.778 | 2.786 | 418 | 4.763 | 703 | 294 | 3.468 | 0 | - |
| Inventories | 3.021 | 4.061 | 2.462 | 251 | 3.956 | 556 | 63 | 3.403 | 0 | - |
| Receivables | 372 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Cash | 63 | 715 | 321 | 167 | 806 | 147 | 231 | 65 | 0 | - |
| Shareholders Funds | -25.020 | -31.302 | -40.804 | -48.259 | -54.629 | -60.150 | -65.827 | -71.192 | -74.671 | - |
| Social Capital | 229 | 227 | 223 | 219 | 215 | 211 | 206 | 207 | 206 | - |
| Debts | 28.475 | 36.080 | 43.590 | 48.676 | 59.392 | 60.853 | 66.121 | 74.660 | 74.671 | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4711 - 4711" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Andocrin S.r.l.